Stock Events

Stock Events

Citius Pharmaceuticals 

0
227
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17DecExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-1.14
-0.64
-0.14
0.36
Expected EPS
-0.352272
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-33.77MNet Income

Analyst Ratings

3.04Average Price Target
The highest estimate is 3.04.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 47N0.F. It's not an investment recommendation.
Apple
29
AAPL
NVIDIA
24
NVDA
Microsoft
21
MSFT
Tesla
20
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap162.16B
Pfizer is a global pharmaceutical company that competes with Citius Pharmaceuticals in the development and marketing of medical treatments, including those in areas where Citius is active.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson, through its pharmaceutical segment, competes across various therapeutic areas, potentially overlapping with Citius Pharmaceuticals' product pipeline.
Merck
MRK
Mkt Cap370.89B
Merck & Co. is involved in the discovery, development, manufacturing, and marketing of pharmaceuticals in areas that may compete with Citius Pharmaceuticals' interests.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie operates in the pharmaceutical industry, focusing on immunology, oncology, and other areas that could directly compete with Citius Pharmaceuticals' projects.
AMGEN
AMGN
Mkt Cap236.38B
Amgen focuses on human therapeutics, including treatments in areas that might overlap with Citius Pharmaceuticals' research and development efforts.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in areas potentially competitive with Citius Pharmaceuticals' portfolio.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol Myers Squibb is a global biopharmaceutical company with a broad range of products that could compete with Citius Pharmaceuticals in several therapeutic areas.
Novartis
NVS
Mkt Cap304.1B
Novartis is a global healthcare company that operates in segments that could directly compete with Citius Pharmaceuticals, especially in drug development and innovation.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company with a wide range of products that could compete with Citius Pharmaceuticals in various therapeutic areas.
Sanofi
SNY
Mkt Cap106.01B
Sanofi is a global healthcare leader that develops and markets drugs in several fields, including those where Citius Pharmaceuticals is seeking to make advancements.

About

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Show more...
CEO
Leonard L. Mazur
Employees
23
Country
United States
ISIN
US17322U3068
WKN
000A40MD0

Listings

F
DE
47N0.F
MU
DE
47N.MU
STU
DE
47N0.STU
MU
DE
47N0.MU

0 Comments

Share your thoughts

FAQ

What is Citius Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Citius Pharmaceuticals stocks are traded under the ticker 47N0.F.
When is the next Citius Pharmaceuticals earnings date?▼
Citius Pharmaceuticals is going to release the next earnings report on December 17, 2026.
What were Citius Pharmaceuticals earnings last quarter?▼
47N0.F earnings for the last quarter are -0.29 EUR per share, whereas the estimation was -0.31 EUR resulting in a +5.56% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Citius Pharmaceuticals revenue for the last year?▼
Citius Pharmaceuticals revenue for the last year amounts to 0 EUR.
What is Citius Pharmaceuticals net income for the last year?▼
47N0.F net income for the last year is -33.77M EUR.
How many employees does Citius Pharmaceuticals have?▼
As of September 10, 2026, the company has 23 employees.
In which sector is Citius Pharmaceuticals located?▼
Citius Pharmaceuticals operates in the Health & Wellness sector.
When did Citius Pharmaceuticals complete a stock split?▼
The last stock split for Citius Pharmaceuticals was on November 26, 2024 with a ratio of 1:25.
Where is Citius Pharmaceuticals headquartered?▼
Citius Pharmaceuticals is headquartered in CRANFORD, United States.